Trial Profile
A 1 Year Randomized, Controlled, Open-Label Study of the Impact of Flexible Doses of Niacin (Niaspan) as an Adjunct To Antipsychotic Medication in the Treatment of First Episode Psychosis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Aug 2015
Price :
$35
*
At a glance
- Drugs Niacin (Primary) ; Antipsychotics
- Indications Psychotic disorders; Schizoaffective disorder; Schizophrenia
- Focus Therapeutic Use
- 06 Aug 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 06 Aug 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 01 Nov 2012 Planned end date changed from 1 Jan 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.